MARKET

BHVN

BHVN

Biohaven Pharma
NYSE

Real-time Quotes | Nasdaq Last Sale

34.03
+0.72
+2.16%
After Hours: 34.03 0 0.00% 17:30 03/31 EDT
OPEN
33.30
PREV CLOSE
33.31
HIGH
35.83
LOW
33.21
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
67.86
52 WEEK LOW
26.56
MARKET CAP
1.98B
P/E (TTM)
-3.1031
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BHVN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BHVN stock price target is 66.20 with a high estimate of 100.00 and a low estimate of 37.00.

EPS

BHVN News

More
  • Oppenheimer Maintains Perform on Biohaven Pharmaceutical, Lowers Price Target to $37
  • Benzinga · 15h ago
  • Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy
  • PR Newswire · 16h ago
  • Biohaven's rimegepant effective in preventing migraine in study
  • Seeking Alpha - Article · 1d ago
  • Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine
  • PR Newswire · 1d ago

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About BHVN

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
More

Webull offers kinds of Biohaven Pharmaceutical Holding Co Ltd stock information, including NYSE:BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions.